Creabilis

About:

Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.

Website: http://www.creabilis-sa.com

Twitter/X: creabilis_sa

Top Investors: Sofinnova Partners, Neomed Management, Abbott Biotech Ventures

Description:

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

Total Funding Amount:

$51.4M

Headquarters Location:

Samone, Emilia-Romagna, Italy

Founded Date:

2003-01-01

Contact Email:

info(AT)creabilis-sa.com

Founders:

Alfredo Boni

Number of Employees:

1-10

Last Funding Date:

2011-10-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai